AU2017381059B2 - 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment - Google Patents

3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment Download PDF

Info

Publication number
AU2017381059B2
AU2017381059B2 AU2017381059A AU2017381059A AU2017381059B2 AU 2017381059 B2 AU2017381059 B2 AU 2017381059B2 AU 2017381059 A AU2017381059 A AU 2017381059A AU 2017381059 A AU2017381059 A AU 2017381059A AU 2017381059 B2 AU2017381059 B2 AU 2017381059B2
Authority
AU
Australia
Prior art keywords
clp
ctrl
fed
lean
obese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017381059A
Other languages
English (en)
Other versions
AU2017381059A1 (en
Inventor
Chloë GOOSSENS
Lies Langouche
Greet Van Den Berghe
Ilse Vanhorebeek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KU Leuven
Original Assignee
KU Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KU Leuven filed Critical KU Leuven
Priority claimed from PCT/EP2017/081394 external-priority patent/WO2018114309A1/en
Publication of AU2017381059A1 publication Critical patent/AU2017381059A1/en
Application granted granted Critical
Publication of AU2017381059B2 publication Critical patent/AU2017381059B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017381059A 2016-12-23 2017-12-04 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment Active AU2017381059B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438771P 2016-12-23 2016-12-23
US62/438,771 2016-12-23
LU100353 2017-08-01
LU100353 2017-08-01
PCT/EP2017/081394 WO2018114309A1 (en) 2016-12-23 2017-12-04 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Publications (2)

Publication Number Publication Date
AU2017381059A1 AU2017381059A1 (en) 2019-07-25
AU2017381059B2 true AU2017381059B2 (en) 2023-11-30

Family

ID=60582587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017381059A Active AU2017381059B2 (en) 2016-12-23 2017-12-04 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Country Status (10)

Country Link
US (2) US20190314307A1 (enExample)
EP (1) EP3558291A1 (enExample)
JP (1) JP7174428B2 (enExample)
KR (1) KR20190099469A (enExample)
CN (1) CN110248652B (enExample)
AU (1) AU2017381059B2 (enExample)
BR (1) BR112019012899A2 (enExample)
CA (1) CA3047362A1 (enExample)
CO (1) CO2019007531A2 (enExample)
MX (1) MX390420B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666548B2 (en) 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
US20240269096A1 (en) * 2022-12-31 2024-08-15 American Ketone Therapeutics LLC Rapid Onset Therapeutic Ketosis Enabled by D-BetaHydroxyButyric Acid Systems, Compounds and Methods for Sepsis Protection and Enhanced Medical Recovery
CN117243939B (zh) * 2023-11-14 2025-03-07 南京今冉生物新材料科技有限公司 一种酮体缓释物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2015018913A1 (en) * 2013-08-07 2015-02-12 Tdeltas Limited Ketone body and ketone body ester for reducing muscle breakdown

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338090C (en) * 1998-07-22 2009-07-14 Metabolix, Inc. Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies
CA2339941A1 (en) * 1998-09-15 2000-03-23 Btg International Limited Use of cyclic esters of r-3-hydroxybutyrate for treatment of metabolic and neural degenerative disorders
CN100344280C (zh) * 2005-08-01 2007-10-24 清华大学 3－羟基丁酸及其衍生物的新用途
ES2655367T3 (es) * 2008-08-21 2018-02-19 Oxford University Innovation Limited Bebida que comprende éster de hidroxibutirato y uso médico de la misma
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2015018913A1 (en) * 2013-08-07 2015-02-12 Tdeltas Limited Ketone body and ketone body ester for reducing muscle breakdown

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, vol. 75(3), JPN6021048755, 1987, pages 533 - 541, ISSN: 0004654945 *
CIRCULATORY SHOCK, vol. 14, JPN6021048754, 1984, pages 63 - 79, ISSN: 0004654947 *
CRITICAL CARE MEDICINE, vol. 28(1), JPN6021048749, 2000, pages 114 - 119, ISSN: 0004654950 *
FEDERATION PROCEEDINGS, vol. 40(3), JPN6021048752, 1981, pages 919, ISSN: 0004654948 *
METABOLISM, vol. 39(11), JPN6021048753, 1990, pages 1151 - 1157, ISSN: 0004654946 *
Planas et al., "Ketone bodies in sepsis" J Clin Nutrition and Gastr, 1988, ES, vol 3, no 4, 134-138 *
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 64, JPN6021048751, 1979, pages 1565 - 1572, ISSN: 0004654949 *
THE LANCET, vol. 1, JPN6021048747, 2013, pages 621 - 629, ISSN: 0004654951 *
VASSILI VALAYANNOPOULOS等: "Successful Treatment of Severe Cardiomyopathy in Glycogen Storage Disease Type III With D,L-3-Hydroxybutyrate, Ketogenic and High-Protein Diet", 《PEDIATRIC RESEARCH》 *

Also Published As

Publication number Publication date
KR20190099469A (ko) 2019-08-27
BR112019012899A2 (pt) 2019-12-03
CN110248652B (zh) 2023-05-26
JP2020502202A (ja) 2020-01-23
US20230310353A1 (en) 2023-10-05
CO2019007531A2 (es) 2020-01-17
MX390420B (es) 2025-03-20
US20190314307A1 (en) 2019-10-17
AU2017381059A1 (en) 2019-07-25
MX2019007597A (es) 2019-12-19
NZ755274A (en) 2025-09-26
CA3047362A1 (en) 2018-06-28
US12409159B2 (en) 2025-09-09
JP7174428B2 (ja) 2022-11-17
EP3558291A1 (en) 2019-10-30
CN110248652A (zh) 2019-09-17

Similar Documents

Publication Publication Date Title
WO2018114309A1 (en) 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment
US12409159B2 (en) 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment
Wilson et al. Effects of beta-hydroxy-beta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex, and training experience: A review
EP2135607A1 (en) Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
Poffé et al. Exogenous ketosis elevates circulating erythropoietin and stimulates muscular angiogenesis during endurance training overload
JP2021001194A (ja) 腸透過性亢進を治療するための組成物及び方法
JP2002518440A (ja) β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
EP2240170B1 (en) Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
Brunt et al. Suppression of trimethylamine N-oxide with DMB mitigates vascular dysfunction, exercise intolerance, and frailty associated with a Western-style diet in mice
JP6858131B2 (ja) 自閉症を治療するための組成物及び方法
NZ575655A (en) Nutrient sensor
Devisscher et al. Romifidine as a constant rate infusion in isoflurane anaesthetized horses: a clinical study
HUE025097T2 (en) Pharmaceutical preparation for preventing intestinal dysbiosis during antibiotic therapy
Bigby et al. Postinduction apnoea in dogs premedicated with acepromazine or dexmedetomidine and anaesthetized with alfaxalone or propofol
DE10035227A1 (de) Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
RS63558B1 (sr) Estri azelainske kiseline u lečenju insulinske rezistencije
CN105025717A (zh) 改善患有肝性脑病的受试者的长期生存和降低其再住院率的方法
US20070066567A1 (en) Use of phospholipid arachidonic acids for increasing muscle mass in humans
Haws et al. A phase 3 trial in participants with obesity due to Bardet-Biedl syndrome or Alström syndrome: efficacy and safety of the melanocortin 4 receptor agonist setmelanotide
Bustos et al. HEMODYNAMIC RESPONSES TO THE COLD PRESSOR TEST IN INDIVIDUALS WITH METABOLIC SYNDROME: 469
WO2024237316A1 (ja) エポキシ化不飽和脂肪酸の皮膚線維化改善作用
JP2019137631A (ja) 血糖値上昇抑制剤
JP2025084032A (ja) グルコン酸亜鉛塩およびシクロ－ヒスプロを有効成分として含む肥満および糖尿病の予防、改善または治療用組成物
KR20070042963A (ko) 당뇨병 환자의 신경병 통증 치료용 약제의 제조를 위한아세틸 엘 카르니틴의 용도
US20180042882A1 (en) C16:1n7-PALMITOLEATE AND DERIVATIVES THEREOF FOR TREATING OBESITY, PROMOTING WEIGHT LOSS, AND SUPPORTING WEIGHT MANAGEMENT

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)